Elicio Therapeutics (ELTX) Amortization of Deferred Charges (2020 - 2021)

Elicio Therapeutics (ELTX) reported Amortization of Deferred Charges of $1.9 million for Q1 2021, up 1100.0% on a YoY basis from $157000.0 in Q1 2020, and down 61.72% quarter-over-quarter from $4.9 million in Q4 2020.

Elicio Therapeutics (ELTX) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends

Elicio Therapeutics has reported Amortization of Deferred Charges for 2 years, with the latest figure at $1.9 million in Q1 2021.

  • For the quarter ending Q1 2021, Amortization of Deferred Charges rose 1100.0% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (down 75.41% YoY), and the FY2021 full-year result was $1.9 million, down 75.41% from the prior year.
  • Amortization of Deferred Charges for Q1 2021 stood at $1.9 million, down from $4.9 million in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $4.9 million in Q4 2020, with the low at $157000.0 in Q1 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn -
7 Psyence Biomedical 251.43 Bn 251.42 Bn -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn
9 Abivax 94.37 Bn 94.37 Bn -
10 Elicio Therapeutics 245.49 Mn 230.55 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2021 1.88 Mn
Mar 31, 2021 1.88 Mn
Dec 31, 2020 4.92 Mn
Dec 31, 2020 4.92 Mn
Sep 30, 2020 2.19 Mn
Sep 30, 2020 2.19 Mn
Jun 30, 2020 396,000.00
Jun 30, 2020 396,000.00
Mar 31, 2020 157,000.00
Mar 31, 2020 157,000.00